Skip to Content

Tocilizumab Does Not Prevent Intubation, Death in COVID-19

THURSDAY, Oct. 22, 2020 -- For moderately ill hospitalized patients with COVID-19, tocilizumab is not effective for preventing intubation or death, according to a study published online Oct. 21 in the New England Journal of Medicine.

John H. Stone, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues conducted a randomized trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 infection, hyperinflammatory states, and at least two of: fever, pulmonary infiltrates, and need for supplemental oxygen to maintain oxygen saturation >92 percent. Two hundred forty-three patients were randomly assigned to receive either standard care plus a single dose of tocilizumab or placebo in a 2:1 ratio.

The researchers found that the hazard ratio for intubation or death was 0.83 (95 percent confidence interval, 0.38 to 1.81; P = 0.64) for tocilizumab versus placebo, and for disease worsening, the hazard ratio was 1.11 (95 percent confidence interval, 0.59 to 2.10; P = 0.73). At 14 days, 18.0 and 14.9 percent of patients in the tocilizumab and placebo groups, respectively, had had disease worsening. The median time to discontinuation of supplemental oxygen was 5.0 and 4.9 days in the tocilizumab and placebo groups, respectively (P = 0.69). At 14 days, 24.6 and 21.2 percent of patients receiving tocilizumab and placebo, respectively, were still receiving supplemental oxygen. Fewer serious infections occurred in patients receiving tocilizumab versus placebo.

"We demonstrated very clearly that, for patients with the disease severity we studied, the use of IL-6 receptor blockade is not warranted," Stone said in a statement.

The study was funded by Genentech, the manufacturer of tocilizumab.

Abstract/Full Text
Editorial

© 2021 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...

Total Pediatric ED Visits Decreased in 2020 Versus 2018, 2019

FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...

Tocilizumab Does Not Improve Outcomes in Severe COVID-19

THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.